Research programme: human papillomavirus therapeutics - Celldex Therapeutics ImmunotherapeuticsAlternative Names: CDX-2410
Latest Information Update: 26 Sep 2008
At a glance
- Originator Celldex Therapeutics Inc
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Human papillomavirus infections
Most Recent Events
- 23 Feb 2007 Preclinical trials in Human papillomavirus infections in USA (unspecified route)